Relapse Prevention for Bipolar Type-II Disorder
| Status: | Completed |
|---|---|
| Conditions: | Depression, Psychiatric, Bipolar Disorder |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 4/21/2016 |
| Start Date: | February 2001 |
| End Date: | January 2007 |
Relapse Prevention of Bipolar Type-II Disorder
This 62-week study will compare the safety and effectiveness of fluoxetine (Prozac®),
lithium, the combination of these two medications, and placebo in treating and preventing
recurrent depressive episodes in people with bipolar type II disorder.
lithium, the combination of these two medications, and placebo in treating and preventing
recurrent depressive episodes in people with bipolar type II disorder.
Bipolar II (BP II) disorder is characterized by a high recurrence of major depressive
episodes (MDE), and it is associated with substantial illness and deaths. Unfortunately,
relatively little attention has been given to treatment of BP II. Concern that patients may
switch from depressed to manic states during treatment of MDE has impeded the development of
effective treatments for BP II MDE.
BP II MDE patients are treated initially with fluoxetine for 10 weeks. Patients who recover
from MDE are then randomized to receive a relapse-prevention treatment of fluoxetine,
lithium, a combination of fluoxetine and lithium, or placebo for 1 year. Patients undergo
clinical and laboratory evaluations, including physical examinations, bloodwork, thyroid
function tests, electrocardiogram (ECG), urinalysis, and HAM-D, YMR, CGI-S, CGI-I, and
adverse events scales.
For information on a related study, please follow this link:
http://clinicaltrials.gov/show/NCT00602537
episodes (MDE), and it is associated with substantial illness and deaths. Unfortunately,
relatively little attention has been given to treatment of BP II. Concern that patients may
switch from depressed to manic states during treatment of MDE has impeded the development of
effective treatments for BP II MDE.
BP II MDE patients are treated initially with fluoxetine for 10 weeks. Patients who recover
from MDE are then randomized to receive a relapse-prevention treatment of fluoxetine,
lithium, a combination of fluoxetine and lithium, or placebo for 1 year. Patients undergo
clinical and laboratory evaluations, including physical examinations, bloodwork, thyroid
function tests, electrocardiogram (ECG), urinalysis, and HAM-D, YMR, CGI-S, CGI-I, and
adverse events scales.
For information on a related study, please follow this link:
http://clinicaltrials.gov/show/NCT00602537
Inclusion Criteria:
- Bipolar II Depression
We found this trial at
1
site
Click here to add this to my saved trials
